Lilly Targets Shingles, Staph and Epstein-Barr in Vaccine Expansion
Highlights Eli Lilly and Company is returning aggressively to the vaccines and infectious disease sector through three acquisitions valued at nearly $4 billion combined. The deals target vaccines for shingles,…